InMode Q3 2026 Revenue Hits $92.1M, Full-Year Outlook Reaffirmed
InMode reported $92.1 million in GAAP revenue for Q3 2026 and maintained its full-year financial guidance.
InMode Ltd., the Nasdaq-listed Israeli medical technology company, posted third-quarter 2026 GAAP revenues of $92.1 million, the company announced Wednesday from its headquarters in Yokneam, Israel. The figures represent the latest financial benchmark for a firm that markets minimally invasive and non-invasive medical devices globally.
Alongside the revenue disclosure, InMode reaffirmed its full-year 2026 financial outlook, signaling management confidence in the company's trajectory through the remainder of the fiscal year. The reaffirmation suggests the business is tracking in line with previously communicated expectations despite broader macroeconomic pressures facing the medical technology sector.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
InMode operates across international markets, positioning itself as a provider of platform technologies used primarily in aesthetic and surgical applications. Quarterly results of this nature offer investors a periodic gauge of demand trends for elective medical procedures, which can be sensitive to consumer spending conditions.
The company's ability to hold its annual guidance steady after the third quarter reduces near-term uncertainty for shareholders heading into the final reporting period of 2026. Analysts tracking the medical device space will likely weigh the revenue figure against sector peers when assessing relative performance.
Continue reading at Earnings for the full breakdown of InMode's Q3 2026 financial results.